AstraZeneca PLC (AZN) vs Merck & Co., Inc. (MRK)
AstraZeneca PLC and Merck & Co., Inc. are both Drug Manufacturers General companies. Merck & Co., Inc. is the larger, with a market value of $365.4B against $257.8B — 1.4× the size. AstraZeneca PLC trades at the lower P/E: 24.7× against 119×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 4.64%. AstraZeneca PLC has the higher net margin (17.0% vs 4.77%) and the higher return on invested capital (11.7% vs 5.08%). Both pay a dividend; Merck & Co., Inc. yields more (2.58% vs 2.49%). Across the 23 metrics below, AstraZeneca PLC leads on 18 and Merck & Co., Inc. on 5.
Valuation
Profitability
| Metric | AZN | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.88% | 72.97% | 72.77% |
| Operating margin | 22.77% | 10.49% | 18.90% |
| Net margin | 17.02% | 4.77% | 8.27% |
| Free cash flow margin | 10.21% | 24.13% | 17.25% |
| Return on equity | 21.95% | 6.97% | 6.97% |
| Return on assets | 9.15% | 2.57% | 2.76% |
| Return on invested capital | 11.67% | 5.08% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack